Glaxosmithkline (GSK)

 

GSK Share PerformanceMore

52 week high1,724.5 22/06/17
52 week low1,294.0 21/11/17
52 week change -210.5 (-13.89%)
4 week volume234,792,399 27/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ViiV Juluca approved in US, says GSK

ViiV Healthcare, the global specialist HIV company, majority-owned by GlaxoSmithKline, with Pfizer and Shionogi Limit...

ViiV Juluca approved in US as first 2-drug regimen

RNS Number: 1659X GlaxoSmithKline PLC 21 November 2017 PRESS RELEASE Juluca (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection London, 21 November 2017 - ViiV Healthcare, the global specialist HIV company, majority...

GSK publishes 2018 dividend dates

RNS Number: 1339X GlaxoSmithKline PLC 21 November 2017 GlaxoSmithKline plc GSK publishes provisional dividend dates GSK announces the following dividend dates for 2017 and 2018: Results announcement date Ex-dividend date* Record date Last date for DRIP elections Payment date Q4 2017 7 February 2018 22 February 2018 23 February 2018 20 March 2018...

Broker Forecast - Jefferies International issues a broker note on GlaxoSmithKline PLC

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price ta...

Trelegy Ellipta EU approval for treatment of COPD

RNS Number: 6797W GlaxoSmithKline PLC 16 November 2017 Issued: 16 November 2017, London UK - LSE Announcement Trelegy Ellipta once-daily single inhaler triple therapy gains marketing authorisation in Europe for the treatment of COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Co...

Director/PDMR Shareholding

RNS Number: 2011W GlaxoSmithKline PLC 10 November 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market partic...

Block listing Interim Review

RNS Number: 1021W GlaxoSmithKline PLC 09 November 2017 BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically and provided to an ris . Date: 09 November 2017 Name of applicant: GlaxoSmithKline plc Name of scheme: GlaxoSmithKline Share Option Plan - Ordinary Shares Period of return: F...

Time to buy bombed-out Hikma Pharmaceuticals?

They've been through the mill this year, losing almost 60% of their value, but Graeme Evans has found an expert backing...

Fundamental DataMore

P/E ratio69.415
EPS18.8
Dividend yield6.13 %

Latest discussion posts More

  • Re: Developments afoot? The dividend

    OK, some good comments there re the dividend question, thanks. I had not read the Q3 earning call transcript. I note the phrase: "The Board intends to maintain the dividend FOR ...
    22-Nov-2017
    kolwezimundele
  • Juluca FDA Approved

    Today's RNS suggests Juluca approval marks a significant step forward in HIV-1 treatment, more signs that GSK is getting some things right in the way it conducts its core ...
    22-Nov-2017
    Hydrogen Economy
  • ViiV Juluca approved in US, says GSK

    ViiV Healthcare, the global specialist HIV company, majority-owned by GlaxoSmithKline, with Pfizer and Shionogi Limited as shareholders, today announced that the US Food and ...
    22-Nov-2017
    Proverbs 26 vs 5

Users' HoldingsMore

Users who hold Glaxosmithkline also hold..
VODAFONE GRP.34%
BP34%
LLOYDS GRP.33%
NATIONAL GRID32%
RDS 'B'31%

Codes & Symbols

ISINGB0009252882
SymbolsGSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account